- SEK3.99bn
- SEK3.72bn
- SEK627.69m
Brief: Probi Signs Collaboration Agreement With Tervisetehnoloogiate Arenduskeskus
Brief: Probi Q1 EBITDA Rises To SEK 47.1 Million
Brief: Probi And China National Pharmaceutical Foreign Trade Corporation Sign License & Supply Agreement
Brief: Probi And Sinopharm Enter Strategic Partnership In China
Brief: Probi Signs Agreement With Perrigo For Launch Of Probiotic Concepts
Brief: Probi Q4 EBITDA Down At SEK 47.0 Million
Brief: Probi Q3 Net Sales Rise To SEK 195 Mln
Brief: Probi Acquires Shares In Vital Nutrients Holdings And Enters Into Strategic Partnership
Brief: Q2 2020 Probi Raises Long-Term Financial Targets
Brief: Probi And Örebro University To Collaborate On Research Into Exploration Of Novel, Needle Free Vaccines
Brief: Probi Q1 Net Sales Rise To SEK 158 Mln
Brief: Probi And Viva5 Announce Strategic Joint Venture
Brief: Prob Q4 Operating Profit Rises To SEK 34.5 Million
Brief: Probi Q3 Operating Profit Falls To SEK 26.7 Million
Brief: Probi Ajusts FY Guidance Due To Weaker Market Growth In US
Brief: Probi Q2 Operating Profit Grows To SEK 39.1 Mln
Swedish stocks: Seen opening slightly higher in line with Europe
Brief: Probi: Probi FerroSorb Concept Effective In Preventing Iron Deficiency Anemia During Pregnancy
Brief: Probi Q1 Operating Profit Rises To SEK 11.3 Million